Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus immune checkpoint inhibitor for advanced or unresectable cholangiocarcinoma and pancreatic cancer
ChiCTR2600134116Phase 2Completed
- Sponsor
- Kaifeng Central Hospital
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in cholangiocarcinoma (CCA), intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA) and 3 more, sponsored by Kaifeng Central Hospital. Primary endpoints: Progression-free survival and Objective response rate. Started Jan 2023; status: completed.
02
Drugs
anlotinib
03
Conditions
cholangiocarcinoma (CCA)intrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancerAmpullary cancer (AC)
Beyond the preview
Go deeper on ChiCTR2600134116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134116.